These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22582908)

  • 21. Diagnostic approach and treatment of cutaneous lupus erythematosus.
    Sticherling M; Bonsmann G; Kuhn A
    J Dtsch Dermatol Ges; 2008 Jan; 6(1):48-59. PubMed ID: 18190433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.
    Chasset F; Arnaud L; Jachiet M; Monfort JB; Bouaziz JD; Cordoliani F; Bagot M; Barbaud A; Francès C
    J Am Acad Dermatol; 2018 Jan; 78(1):107-114.e1. PubMed ID: 29061479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linear cutaneous lupus erythematosus in the lines of Blaschko.
    Engelman DE; Kotz EA; Maize JC
    Pediatr Dermatol; 2007; 24(2):125-9. PubMed ID: 17461806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
    Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
    J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.
    Avgerinou G; Papafragkaki DK; Nasiopoulou A; Arapaki A; Katsambas A; Stavropoulos PG
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):762-7. PubMed ID: 21707772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.
    Yokogawa N; Eto H; Tanikawa A; Ikeda T; Yamamoto K; Takahashi T; Mizukami H; Sato T; Yokota N; Furukawa F
    Arthritis Rheumatol; 2017 Apr; 69(4):791-799. PubMed ID: 27992698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effect of hydroxychloroquine on cutaneous lupus erythematosus in a Japanese girl.
    Yamamoto T; Hiraiwa T
    J Dermatol; 2014 Apr; 41(4):357-9. PubMed ID: 24617496
    [No Abstract]   [Full Text] [Related]  

  • 28. Rosacea-like cutaneous lupus erythematosus: an atypical presentation responding to antimalarials.
    Marzano AV; Lazzari R; Polloni I; Boneschi V; Crosti C
    Acta Derm Venereol; 2013 Jan; 93(1):106-7. PubMed ID: 23053047
    [No Abstract]   [Full Text] [Related]  

  • 29. Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain.
    Arévalo-Bermúdez MDP; Paradela S; Balboa-Barreiro V; Fonseca E
    Lupus; 2020 Aug; 29(9):1021-1030. PubMed ID: 32539659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
    Momose Y; Arai S; Eto H; Kishimoto M; Okada M
    J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subacute cutaneous lupus erythematosus: a paraneoplastic dermatosis?
    Chaudhry SI; Murphy LA; White IR
    Clin Exp Dermatol; 2005 Nov; 30(6):655-8. PubMed ID: 16197381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Classification of dermatologic manifestations in lupus erythematosus].
    Francès C; Barete S; Ayoub N; Piette JC
    Ann Med Interne (Paris); 2003 Feb; 154(1):33-44. PubMed ID: 12746657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
    Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
    Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus.
    Rahman P; Gladman DD; Urowitz MB
    J Rheumatol; 1998 Sep; 25(9):1716-9. PubMed ID: 9733451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
    Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
    Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
    Parke A; West B
    J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients.
    Ototake Y; Yamaguchi Y; Kanaoka M; Akita A; Ikeda N; Aihara M
    J Dermatol; 2019 Apr; 46(4):285-289. PubMed ID: 30719729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.
    Stannard JN; Kahlenberg JM
    Curr Opin Rheumatol; 2016 Sep; 28(5):453-9. PubMed ID: 27270345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Mittal L; Zhang L; Feng R; Werth VP
    J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.
    Sisó A; Ramos-Casals M; Bové A; Brito-Zerón P; Soria N; Muñoz S; Testi A; Plaza J; Sentís J; Coca A
    Lupus; 2008 Apr; 17(4):281-8. PubMed ID: 18413408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.